| Mission | People | Technology R&D | Patents and Publications | Facilities Environment | Tools and Resources | Technology Training and Dissemination |
Living cells are emerging as a new generation of bioactive therapeutics. However, the high costs of current state-of-the-art cell manufacturing methods, along with the logistics of cell storage and transport, remain major barriers to the widespread adoption of living cell-based therapies. The low in-vivo cell survival rate further limits the potential impact of these treatments. The overall mission of The Advanced Cell Manufacturing and Therapies Program (ACT) at Penn State is to develop a ground-breaking, miniaturized production system for low-cost large-scale cell manufacturing and functionalization. It can be utilized for both centralized and decentralized point-of-care cell manufacturing, enabling fast, affordable, reliable, and on-demand production, as well as on-site cell-friendly functionalization in hospitals or laboratories.
